Midostaurin or quizartinib in newly diagnosed FLT3-ITD AML?

Both have 1L approval. Quizartinib (QuANTUM-First) showed OS benefit specific to FLT3-ITD. Midostaurin (RATIFY) covers FLT3-ITD and FLT3-TKD broadly. Quizartinib has more pronounced QT/cardiac AE signal. Institutional preference, AE profile, ITD vs TKD status, and access drive the call.

Does allelic ratio still drive the transplant decision?

High FLT3-ITD AR (≥0.5) historically favored allo SCT in CR1. With effective FLT3 inhibitors and post-transplant maintenance (gilteritinib MORPHO data), the equation is evolving. Most centers still recommend transplant for high-AR ITD, but the urgency has softened.

What about FLT3-TKD without ITD?

FLT3-TKD alone has a less adverse prognosis than ITD. Midostaurin covers FLT3-TKD; quizartinib's label is FLT3-ITD specific. Gilteritinib has activity against both. Treatment selection still favors FLT3-inhibitor-containing regimens.

Variant cheat sheet · acute myeloid leukemia

FLT3-ITD and FLT3-TKD in acute myeloid leukemia

Free clinical reference. Educational use only — not a substitute for professional medical advice.

TL;DR

FLT3 mutations (ITD or TKD) in AML are AMP/ASCO/CAP Tier I-A. Midostaurin + intensive chemotherapy (RATIFY) is established 1L for fit patients. Quizartinib + chemotherapy (QuANTUM-First) for newly diagnosed FLT3-ITD. Gilteritinib for R/R disease (ADMIRAL). Allelic ratio (FLT3-ITD AR) and NPM1 co-mutation status modulate prognosis and transplant timing.

Biology

FLT3 is a class III receptor tyrosine kinase essential for early hematopoiesis. Internal tandem duplications (ITDs) in the juxtamembrane domain cause ligand-independent dimerization and constitutive STAT5 / MAPK / PI3K signaling. TKD point mutations (most commonly D835) produce a similar activated state by a different mechanism. Both confer proliferative advantage; ITD with high allelic ratio is the more adverse prognostic class.

Epidemiology

FLT3-ITD occurs in ~25-30% of AML; FLT3-TKD in ~7-10%. ITD with high allelic ratio (AR ≥ 0.5) historically favors allogeneic stem cell transplant in first complete remission. NPM1 co-mutation softens the adverse impact; DNMT3A triple-mutant phenotype is particularly high-risk.

Detection

NGS or fragment analysis. Fragment analysis is historically preferred for ITD allelic ratio quantification.
Co-mutation profile (NPM1, DNMT3A, IDH1/2, TP53) is essential for risk stratification.
MRD assessment by qPCR or NGS becomes important post-induction.

FDA-approved targeted therapies

Drug	Indication	Line	Tier
Midostaurin + 7+3 + HiDAC	Newly diagnosed FLT3-mutant AML (RATIFY)	1L (fit)	I-A
Quizartinib + 7+3 + HiDAC	Newly diagnosed FLT3-ITD AML (QuANTUM-First)	1L (fit)	I-A
Gilteritinib	R/R FLT3-mutant AML (ADMIRAL); post-allo SCT maintenance (MORPHO)	R/R; post-SCT maintenance	I-A
Sorafenib (off-label)	Post-allo SCT FLT3-ITD maintenance (SORMAIN)	Maintenance	I-B

Tier = AMP/ASCO/CAP 2017 (Li MM et al., J Mol Diagn 2017). Drug names link to openFDA labels where available. Synthetic data; consult primary sources before treatment.

Resistance pathways

FLT3 secondary kinase-domain mutations (F691L gatekeeper, D835 mutations emerging after type-II FLT3 inhibitors).
Bypass-track activation (RAS, lineage switching to monocytic phenotype).
Pharmacokinetic interactions with strong CYP3A4 inhibitors (azoles, ritonavir).

Pharmacogenomics

FLT3 TKIs are CYP3A4 substrates. Strong CYP3A4 inhibitors increase exposure substantially; combination requires dose reduction or alternative therapy. Quizartinib and midostaurin carry QT prolongation risk; baseline and on-treatment ECG monitoring is required.

Frequently asked questions

Midostaurin or quizartinib in newly diagnosed FLT3-ITD AML?: Both have 1L approval. Quizartinib (QuANTUM-First) showed OS benefit specific to FLT3-ITD. Midostaurin (RATIFY) covers FLT3-ITD and FLT3-TKD broadly. Quizartinib has more pronounced QT/cardiac AE signal. Institutional preference, AE profile, ITD vs TKD status, and access drive the call.
Does allelic ratio still drive the transplant decision?: High FLT3-ITD AR (≥0.5) historically favored allo SCT in CR1. With effective FLT3 inhibitors and post-transplant maintenance (gilteritinib MORPHO data), the equation is evolving. Most centers still recommend transplant for high-AR ITD, but the urgency has softened.
What about FLT3-TKD without ITD?: FLT3-TKD alone has a less adverse prognosis than ITD. Midostaurin covers FLT3-TKD; quizartinib's label is FLT3-ITD specific. Gilteritinib has activity against both. Treatment selection still favors FLT3-inhibitor-containing regimens.